FDA grants fast track designation to TH1902 for sortilin-expressing cancers

The FDA granted fast track designation to TH1902 for treatment of certain patients with sortilin-expressing cancers, according to the agent’s manufacturer.The designation applies to use of the agent as monotherapy for patients with recurrent, advanced solid tumors that are refractory to standard therapy.TH1902 (Theratechnologies) is a peptide drug conjugate that combines the company’s proprietary peptide to docetaxel. The peptide targets sortilin (SORT1) receptors.SORT1 is expressed in several malignancies, including ovarian, skin, lung, colorectal, pancreatic and triple-negativeRead More

Share on facebook
Share on twitter
Share on linkedin